Tscan Therapeutics Inc [TCRX] stock is trading at $2.97, up 1.37%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TCRX shares have gain 4.21% over the last week, with a monthly amount drifted -27.91%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Tscan Therapeutics Inc [NASDAQ: TCRX] stock has seen the most recent analyst activity on May 16, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $12. Previously, Needham started tracking the stock with Buy rating on May 13, 2024, and set its price target to $11. On June 22, 2023, Wedbush initiated with a Outperform rating and assigned a price target of $8 on the stock.
Tscan Therapeutics Inc [TCRX] stock has fluctuated between $2.60 and $9.69 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Tscan Therapeutics Inc [NASDAQ: TCRX] shares were valued at $2.97 at the most recent close of the market. An investor can expect a potential return of 304.04% based on the average TCRX price forecast.
Analyzing the TCRX fundamentals
Tscan Therapeutics Inc [NASDAQ:TCRX] reported sales of 9.36M for the trailing twelve months, which represents a drop of -73.01%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -12.76%, Pretax Profit Margin comes in at -11.89%, and Net Profit Margin reading is -11.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.59 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.88 points at the first support level, and at 2.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.06, and for the 2nd resistance point, it is at 3.14.
Ratios To Look Out For
For context, Tscan Therapeutics Inc’s Current Ratio is 9.56. In addition, the Quick Ratio stands at 9.56 and the Cash Ratio stands at 4.64. Considering the valuation of this stock, the price to sales ratio is 17.17, the price to book ratio is 0.69.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Dec 13 ’24 when 100000.0 shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Dec 12 ’24 to buy 31800.0 shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 947.0 shares on Nov 15 ’24.
